The immune system is essential to survival, and even a modest decrease in immune function can leave a person susceptible to infection. But the immune system itself can also cause disease, by inappropriately attacking the body’s own organs, tissues, or cells (http://www3.niaid.nih.gov/research/topics/autoimmune/introduction.htm).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Davidson, A. and Diamond, B. (2001) Autoimmune diseases, N. Engl. J. Med., 345(5), 340–350.
Sinha, A. A., Lopez, M. T., and McDevitt, H. O. (1990) Autoimmune diseases: the failure of self tolerance, Science, 248, 1380–1388.
Jacobson, D. L., Gange, S. J., Rose, N. R., and Graham N. M. (1997) Epidemiology and estimated population burden of selected autoimmune diseases in the United States, Clin. Immunol. Immunopathol., 84, 223–243.
Dighiero, G. and Rose, N. R. (1999) Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity, Immunol. Today, 20, 423–428.
Goldrath, A. W. and Bevan, M. J. (1999) Selecting and maintaining a diverse T-cell repertoire, Nature, 402, 255–262.
Gu, H., Tarlinton, D., Muller, W., Rajewsky, K., and Forster, I. (1991) Most peripheral B cells in mice are ligand selected, J. Exp. Med., 173, 1357–1371.
Silverstein, A. M. and Rose, N. R. (2000) There is only one immune system! The view from immunopathology, Semin. Immunol., 12, 173–178; 257.
Takahashi, T., Tanaka, M., Brannan, C. I., et al. (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand, Cell, 76, 969–976.
Zhou, T., Edwards, C. K., III, Yang, P., Wang, Z., Bluethmann, H., and Mountz, J. D. (1996) Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I, J. Immunol., 156, 2661–2665.
Dang, H., Geiser, A. G., Letterio, J. J., et al. (1005) SLE-like autoantibodies and Sjogren’s syndrome-like lymphoproliferation in TGF-beta knockout mice, J. Immunol., 155, 3205–3212.
Kontoyiannis, D. and Kollias, G. (2000) Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor, Eur. J. Immunol., 30, 2038–2047.
Napirei, M., Karsunky, H., Zevnik, B., Stephan, H., Mannherz, H. G., and Moroy, T. (2000) Features of systemic lupus erythematosus in Dnase1-deficient mice, Nat. Genet., 25, 177–181.
Bickerstaff, M. C., Botto, M., Hutchinson, W. L., et al. (1999) Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity, Nat. Med., 5, 694–697.
Botto, M. (1998) C1q knock-out mice for the study of complement deficiency in autoimmune disease, Exp. Clin. Immunogenet., 15, 231–234.
Nishizumi, H., Taniuchi, I., Yamanashi, Y., et al. (1995) Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice, Immunity, 3, 549–560.
Westhoff, C. M., Whittier, A., Kathol, S., et al. (1997) DNA-binding antibodies from viable motheaten mutant mice: implications for B cell tolerance, J. Immunol., 159, 3024–3033.
O’Keefe, T. L., Williams, G. T., Davies, S. L., and Neuberger, M.S. (1996) Hyperresponsive B cells in CD22-deficient mice, Science, 274, 798–801.
Tanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., and Nagata, S. (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis, Nature, 356, 314–317.
Gross, J. A., Johnson, J., Mudri, S., et al. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease, Nature, 404, 995–999.
Mandik-Nayak, L., Nayak, S., Sokol, C., et al. (2000) The origin of anti-nuclear antibodies in bcl-2 transgenic mice, Int. Immunol., 12, 353–364.
Nishimura, H., Nose, M., Hiai, H., Minato, N., and Honjo, T. (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor, Immunity, 11, 141–151.
Iizuka, J., Katagiri, Y., Tada, N., et al. (1998) Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies, Lab. Invest., 78, 1523–1533.
Cornall, R. J., Cyster, J. G., Hibbs, M. L., et al. (1998) Polygenic autoimmune traits: Lyn, CD22, and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection, Immunity, 8, 497–508.
Seery, J. P., Carroll, J. M., Cattell, V., and Watt, F. M. (1997) Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing interferon gamma in the epidermis, J. Exp. Med., 186, 1451–1459.
Lopez-Hoyos, M., Carrio, R., Merino, R,, et al. (1996) Constitutive expression of bcl-2 in B cells causes a lethal form of lupuslike autoimmune disease after induction of neonatal tolerance to H-2b alloantigens, J. Exp. Med., 183, 2523–2531.
Bolland, S. and Ravetch, J. V. (2000) Spontaneous autoimmune disease in Fc(gamma) RIIB-deficient mice results from strain-specific epistasis, Immunity, 13, 277–285.
Balomenos, D., Martin-Caballero, J., Garcia, M. I., et al. (2000) The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development, Nat. Med., 6, 171–176.
Bouillet, P., Metcalf, D., Huang, D. C., et al. (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity, Science, 286, 1735–1738.
Chen, Z., Koralov, S. B., and Kelsoe, G. (2000) Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2, J. Exp. Med., 192, 1339–1352.
Sato, S., Ono, N., Steeber, D. A., Pisetsky, D. S., and Tedder, T. F. (1996) CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity, J. Immunol., 157, 4371–4378.
Gorelik, L. and Flavell, R. A. (2000) Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease, Immunity, 12, 171–181.
Di Cristofano, A., Kotsi, P., Peng, Y. F., Cordon-Cardo, C., Elkon, K. B., and Pandolfi, P. P. (1999) Impaired Fas response and autoimmunity in Pten+/–mice, Science, 285, 2122–2125.
Majeti, R., Xu, Z., Parslow, T. G., et al. (2000) An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity, Cell, 103, 1059–1070.
Yuki, N. (1999) Pathogenesis of Guillain-Barré and Miller-Fisher syndromes subsequent to Campylobacter jejuni enteritis, Jpn. J. Infect. Dis., 52, 99–105.
Bhan, A. K., Mizoguchi, E., Smith, R. N., and Mizoguchi, A. (1999) Colitis in transgenic and knockout animals as models of human inflammatory bowel disease, Immunol. Rev., 169, 195–207.
Blumberg, R. S., Saubermann, L. J., and Strober, W. (1999) Animal models of mucosal inflammation and their relation to human inflammatory bowel disease, Curr. Opin. Immunol., 11, 648–656 [Erratum: Curr. Opin. Immunol., 12, 226 (2000)].
Boismenu, R. and Chen, Y. (2000) Insights from mouse models of colitis, J. Leukoc. Biol., 67, 267–278.
Shevach, E. M. (2000) Regulatory T cells in autoimmunity, Annu. Rev. Immunol., 18, 423–449.
Targoff, I. N. (2000) Update on myositis-specific and myositis-associated autoantibodies, Curr. Opin. Rheumatol., 12, 475–481.
Austrup, F., Vestweber, D., Borges, E., et al. (1997) P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues, Nature, 385, 81–83.
von Andrian, U. H. and Mackay, C. R. (2000) T-cell function and migration: two sides of the same coin, N. Engl. J. Med., 343, 1020–1034.
Buyon, J. P., Tseng, C. E., Di Donato, F., Rashbaum, W., Morris, A., and Chan, E. K. (1997) Cardiac expression of 52beta, an alternative transcript of the congenital heart block-associated 52-kd SS-A/Ro autoantigen, is maximal during fetal development, Arthritis Rheum., 40, 655-660.
Edelson, R. L. (2000) Pemphigus - decoding the cellular language of cutaneous autoimmunity, N. Engl. J. Med., 343, 60–61.
Mackay, I. R. (2001) Tolerance and autoimmunity, West J. Med., 174(2), 118–123.
Romagnani, S. (1997) The Th1/Th2 paradigm, Immunol. Today, 18, 263–266.
Sallusto, F., Lanzavecchia, A., and Mackay, C. R. (1999) Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses, Immunol. Today,19, 568–574.
Luster, A.D. (1998) Chemokines - chemotactic cytokines that mediate inflammation, N. Engl. J. Med., 338, 436–445.
Horwitz, M. S., Bradley, L. M., Harbertson, J., Krahl, T., Lee, J., and Sarvetnick, N. (1998) Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry, Nat. Med., 4, 781–785.
Neumann, D. A., Rose, N. R., Ansari, A. A., and Herskowitz, A. (1994) Induction of multiple heart autoantibodies in mice with coxsackievirus B3- and cardiac myosin-induced autoimmune myocarditis, J. Immunol., 152, 343–350.
Oldstone, M. B. A. (1998) Molecular mimicry and immune-mediated diseases, FASEB J., 12, 1255–1265.
Darnell, R. B. (1999) The importance of defining the paraneoplastic neurologic disorders [editorial], N. Engl. J. Med., 340, 1831–1833.
Todd, J. A. (1999) From genome to aetiology in a multifactorial disease, type 1 diabetes, Bioessays, 21, 164–174.
Griffiths, M. M., Encinas, J. A., Remmers, E. F., Kuchroo, V. K., and Wilder, R. L. (1999) Mapping autoimmunity genes, Curr. Opin. Immunol., 11, 689–700.
Wilson, S. B., Kent, S. C., Patton, K. T., et al. (1998) Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes, Nature, 391, 177–181 [Erratum: Nature, 399, 84 (1999)].
Ortonne, J. P. (1999) Recent developments in the understanding of the pathogenesis of psoriasis, Br. J. Dermatol., 140(Suppl. 54), 1–7.
Kukreja, A, and Maclaren, N. K. (1999) Autoimmunity and diabetes, J. Clin. Endocrinol. Metab., 84, 4371–4378.
Gregersen, P. K. (1997) Genetic analysis of rheumatic diseases. In: Textbook of Rheumatology, vol. 1, 5th ed. (Kelley, W. N., Harris, E. D., Jr., Ruddy, S., and Sledge, C. B., eds.), W. B. Saunders, Philadelphia, pp. 209–227.
Drappa, J., Vaishnaw, A. K., Sullivan, K. E., Chu, J.-L., and Elkin, K. B. (1996) Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity, N. Engl. J. Med., 335, 1643–1649.
Pitkanen, J., Vahamurto, P., Krohn, K., and Peterson, P. (2001) Subcellular localization of the autoimmune regulator protein: characterization of nuclear targeting and transcriptional activation domain, J. Biol. Chem., 276(22), 19597–19602.
Wang, C. Y., Davoodi-Semiromi, A., Huang, W., Connor, E., Shi, J. D., and She, J. X. (1998) Characterization of mutations in patients with autoimmune polyglandular syndrome type 1 (APS1), Hum. Genet., 103, 681–685.
Encinas, J. A. and Kuchroo, V. K. (2000) Mapping and identification of autoimmunity genes, Curr. Opin. Immunol., 12, 691–697.
Becker, K. G. (1999) Comparative genetics of type 1 diabetes and autoimmune disease: common loci, common pathways? Diabetes, 48, 1353–1358.
Klein, J. and Sato, A. (2000) The HLA system, N. Engl. J. Med., 343, 782–786.
Taneja, V. and David, C. S. (1999) HLA class II transgenic mice as models of human diseases, Immunol. Rev., 169, 67–79.
Khare, S. D., Luthra, H. S., and David, C. S. (1998) Animal models of human leukocyte antigen B27-linked arthritides, Rheum. Dis. Clin. North Am., 24, 883–894 [Erratum: Rheum. Dis. Clin. North Am., 25: xi-xii (1999)].
Gregersen, P. K., Silver, J., and Winchester, R. J. (1987) The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis, Arthritis Rheum., 30, 1205–1213.
McDaniel, D. O., Alarcon, G. S., Pratt, P. W., and Reveille, J. D. (1995) Most African-American patients with rheumatoid arthritis do not have the rheumatoid antigenic determinant (epitope), Ann. Intern. Med., 123, 181–187.
Teller, K., Budhai, L., Zhang, M., Haramati, N., Keiser, H. D., and Davidson, A. (1996) HLA-DRB1 and DQB typing of Hispanic American patients with rheumatoid arthritis: the “shared epitope” hypothesis may not apply, J. Rheumatol., 23, 1363–1368.
Kouki, T., Sawai, Y., Gardine, C. A., Fisfalen, M. E., Alegre, M. L., and DeGroot, L. J. (2000) CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves’ disease, J. Immunol., 165, 6606–6611.
Agarwal, K., Jones, D. E., Daly, A. K., et al. (2000) CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis, J. Hepatol., 32, 538–541.
Awata, T., Kurihara, S., Iitaka, M., et al. (1998) Association of CTLA-4 gene A-G polymorphism (IDDM12 locus) with acute-onset and insulin-depleted IDDM as well as autoimmune thyroid disease (Graves’ disease and Hashimoto’s thyroiditis) in the Japanese population, Diabetes, 47, 128–129.
Ginn, L. R., Lin, J. P., Plotz, P. H., et al. (1998) Familial autoimmunity in pedigrees of idiopathic inflammatory myopathy patients suggests common genetic risk factors for many autoimmune diseases, Arthritis Rheum., 41, 400–405.
Henderson, R. D., Bain, C. J., and Pender, M. P. (2000) The occurrence of autoimmune diseases in patients with multiple sclerosis and their families, J. Clin. Neurosci., 7, 434–437.
Coelho, S. N., Saleem, S., Konieczny, B. T., Parekh, K. R., Baddoura, F. K., and Lakkis, F. G. (1997) Immunologic determinants of susceptibility to experimental glomerulonephritis: role of cellular immunity, Kidney Int., 51, 646–652.
Liao, L., Sindhwani, R., Rojkind, M., Factor, S., Leinwand, L., and Diamond, B. (1995) Antibody-mediated autoimmune myocarditis depends on genetically determined target organ sensitivity, J. Exp. Med., 181, 1123–1131.
Moudgil, K. D. and Sercarz, E. E. (1994) The T cell repertoire against cryptic self determinants and its involvement in autoimmunity and cancer, Clin. Immunol. Immunopathol., 73, 283–289.
Lanzavecchia, A. (1995) How can cryptic epitopes trigger autoimmunity? J. Exp. Med., 181, 1945–1948.
Vanderlugt, C. L., Neville, K. L., Nikcevich, K. M., Eagar, T. N., Bluestone, J. A., and Miller, S. D. (2000) Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis, J. Immunol., 164, 670–678.
Liang, B. and Mamula, M. J. (2000) Molecular mimicry and the role of B lymphocytes in the processing of autoantigens, Cell. Mol. Life Sci., 57, 561–568.
Thomas, H. E. and Kay, T. W. (2000) Beta cell destruction in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse, Diabetes Metab. Res. Rev., 16, 251–261.
O’Garra, A., Steinman, L., and Gijbels, K. (1997) CD4+ T-cell subsets in autoimmunity, Curr. Opin. Immunol., 9, 872–883.
Juedes, A. E., Hjelmstrom, P., Bergman, C. M., Neild, A. L., and Ruddle, N. H. (2000) Kinetics and cellular origin of cytokines in the central nervous system: insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis, J. Immunol., 164, 419–426.
Genain, C. P., Abel, K., Belmar, N., et al. (1996) Late complications of immune deviation therapy in a nonhuman primate, Science, 274, 2054–2057.
Saoudi, A., Bernard, I., Hoedemaekers, A., et al. (1999) Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats, J. Immunol., 162, 7189–7197.
Balasa, B. and Sarvetnick, N. (2000) Is pathogenic humoral autoimmunity a Th1 response? Lessons from (for) myasthenia gravis, Immunol. Today, 21, 19–23.
Takasu, N., Oshiro, C., Akamine, H., et al. (1997) Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves’ patients and in 686 normal subjects, J. Endocrinol. Invest., 20, 452–461.
Seishima, M., Iwasaki-Bessho, Y., Itoh, Y., Nozawa, Y., Amagai, M., and Kitajima, Y. (1999) Phosphatidylcholine-specific phospholipase C, but not phospholipase D, is involved in pemphigus IgG-induced signal transduction, Arch. Dermatol. Res., 291, 606–613.
Salemink, I., Blezer, R., Willems, G. M., Galli, M., Bevers, E., and Lindhout, T. (2000) Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor, Thromb. Haemost., 84, 653–656.
Merrill, J. T., Zhang, H. W., Shen, C., et al. (1999) Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein, Thromb. Haemost., 81, 748–757.
Madaio, M. P. and Yanase, K. (1998) Cellular penetration and nuclear localization of anti-DNA antibodies: mechanisms, consequences, implications and applications, J. Autoimmun., 11, 535–538.
Reichlin, M. (1998) Cellular dysfunction induced by penetration of autoantibodies into living cells: cellular damage and dysfunction mediated by antibodies to dsDNA and ribosomal P proteins, J. Autoimmun., 11, 557–561.
Johnson, K. P., Brooks, B. R., Cohen, J. A., et al. (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability: Copolymer I Multiple Sclerosis Study Group, Neurology, 50, 701–708.
Feldmann, M., Charles, P., Taylor, P., and Maini, R. N. (1998) Biological insights from clinical trials with anti-TNF therapy, Springer Semin. Immunopathol., 20, 211–228.
Sayegh, M. H. (1999) Finally, CTLA4Ig graduates to the clinic, J. Clin. Invest., 103, 1223–1225.
Tian, J., Olcott, A., Hanssen, L., Zekzer, D., and Kaufman, D. L. (1999) Antigen-based immunotherapy for autoimmune disease: from animal models to humans? Immunol. Today, 20, 190–195.
Tyndall, A., Fassas, A., Passweg, J., et al. (1999) Autologous haematopoietic stem cell transplants for autoimmune disease - feasibility and transplant-related mortality: Autoimmune Disease and Lymphoma Working Parties of the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease, Bone Marrow Transplant., 24, 729–734.
Potter, M., Black, C., and Berger A. (1999) Bone marrow transplantation for autoimmune diseases [editorial], Br. Med. J., 318, 750–751.
Giannoukakis, N., Rudert, W. A., Robbins, P. D., and Trucco, M. (1999) Targeting autoimmune diabetes with gene therapy, Diabetes, 48, 2107–2121.
Maini, R. N. and Taylor, P. C. (2000) Anti-cytokine therapy for rheumatoid arthritis, Annu. Rev. Med., 51, 207–229.
Kremer, J. M. (2001) Rational use of new and existing disease-modifying agents in rheumatoid arthritis, Ann. Intern. Med., 134, 695–706.
Bell, S. and Kamm, M. A. (2000) Antibodies to tumour necrosis factor alpha as treatment for Crohn’s disease, Lancet, 355, 858–860.
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., and Burge, D. J. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial, Lancet, 356, 385–390.
Brandt, J., Haibel, H., Cornely, D., et al. (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab, Arthritis Rheum., 43, 1346–1352.
Emery, P., Breedveld, F. C., Lemmel, E. M., et al. (2000) A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis, Rheumatology (Oxford), 39, 655–665.
Weinblatt, M. E., Kremer, J. M., Coblyn, J. S., et al. (1999) Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis, Arthritis Rheum., 42, 1322–1328.
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., and Weinshenker, B. G. (2000) Multiple sclerosis, N. Engl. J. Med., 343, 938–952.
Jacobs, L. D., Beck, R. W., Simon, J. H., et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis, N. Engl. J. Med., 343, 898–904.
Fridkis-Hareli, M., Neveu, J. M., Robinson, R. A., et al. (1999) Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules, J. Immunol., 162, 4697–4704.
Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I., and Hafler, D. A. (2000) Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis, J. Clin. Invest., 105, 967–976.
Kappos, L., Comi, G., Panitch, H., et al. (2000) Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial, Nat. Med., 6, 1176–1182.
Bielekova, B., Goodwin, B., Richert, N., et al. (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand, Nat. Med., 6, 1167–1175.
Gallon, L., Chandraker, A., Issazadeh, S., et al. (1997) Defferential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model, J. Immunol., 159(9), 4212–4216.
Asadullah, K., Docke, W. D., Sabat, R. V., Volk, H. D., and Sterry, W. (1999) The treatment of psoriasis with IL-10: rationale and review of the first clinical trials, Expert Opin. Investig. Drugs, 9, 95–102.
Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., et al. (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris, J. Clin. Invest., 103, 1243–1252.
Salomon, B., Lenschow, D. J., Rhee, L., et al. (2000) B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes, Immunity, 12, 431–440.
Gottlieb, A. B., Lebwohl, M., Shirin, S., et al. (2000) Anti-CD4 monoclonal antibody treatment of moderate to severe psoriasis vulgaris: results of a pilot, multicenter, multiple-dose, placebo-controlled study, J. Am. Acad. Dermatol., 43, 595–604.
Krueger, J. G., Walters, I. B., Miyazawa, M., et al. (2000) Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis, J. Am. Acad. Dermatol., 43, 448–458.
Krueger, J., Gottlieb, A., Miller, B., Dedrick, R., Garovoy, M., and Walicke, P. (2000) Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking, J. Invest. Dermatol., 115, 333 [abstract].
Gottlieb, A., Krueger, J. G., Bright, R., et al. (2000) Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis, J. Am. Acad. Dermatol., 42, 428–435.
Herold, K. S., Hagopian, W., Auger, J. A., et al. (2002) Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus, N. Engl. J. Med., 346(22), 1692–1698.
Herold, S. K. and Taylor, L. (2003) Treatment of type 1 diabetes with CD3 monoclonal antibody. Induction of immune regulation? Immunol. Res., 28(2), 141–150.
Pozzilli, P., Pitocco, D., Visalli, N., et al. (2000) No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII), Diabetologia, 43, 1000–1004.
Mohan, C., Shi, Y., Laman, J. D., and Datta, S. K. (1995) Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis, J. Immunol., 154, 1470–1480.
Daikh, D. I. and Wofsy, D. (2001) Reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide, J. Immunol., 166, 2913–2916.
Kawai, T., Andrews, D., Colvin, R. B., Sachs, D. H., and Cosimi, A. B. (2000) Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand, Nat. Med., 6, 114–114.
Kalunian, K., Davis, J., Merrill, J. T., et al. (2000) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation, Arthritis Rheum., 43(Suppl.), S271–S271 [abstract].
Llorente, L., Richaud-Patin, Y., Garcia-Padilla, C., et al. (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus, Arthritis Rheum., 43, 1790–1800.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Georgiev, V.S. (2009). Autoimmune Diseases. In: Georgiev, V.S. (eds) National Institute of Allergy and Infectious Diseases, NIH. Infectious Disease. Humana Press. https://doi.org/10.1007/978-1-60327-297-1_41
Download citation
DOI: https://doi.org/10.1007/978-1-60327-297-1_41
Publisher Name: Humana Press
Print ISBN: 978-1-60327-296-4
Online ISBN: 978-1-60327-297-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)